← Back to dossier
Patient handout

Massive (Life-Threatening) Hemoptysis (acute airway emergency)

PRODUCTION

1. Your condition

This handout is for massive (life-threatening) hemoptysis (acute airway emergency). Your care team identified this based on: expectoration of blood / blood-streaked sputum — quantify volume + rate (earwood afp 2015 pmid 25955625).

Other reasons your team may use this plan: hemoptysis with hypoxia / respiratory distress / hypotension — physiologic-massive trigger (charya 2021 pmid 34527355); red-flag escalation from pulm.bronchiectasis.core.v1 / pulm.tuberculosis.v1 / pulm.abpa.v1 when bleeding becomes life-threatening; recent swan-ganz/pa catheter, transbronchial biopsy, or lung procedure — iatrogenic pa rupture risk (charya 2021 pmid 34527355).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
bleeding_side_down_lateral_decubitus_positioningBleeding lung DOWN (when side known/suspected)positioningcontinuousProtects the non-bleeding lung from soiling — asphyxiation, not exsanguination, is the killer (Charya 2021 PMID 34527355)
high_flow_oxygen_and_large_bore_suctionHigh-flow O2 to SpO2 ≥92%; continuous large-bore suctioninhaledcontinuousMaintain oxygenation while clearing airway blood (Charya 2021 PMID 34527355)
selective_intubation_lung_isolationLarge single-lumen ETT (≥8.0) to good lung, OR bronchial blocker, OR double-lumen tubeairwayonceIsolate/protect the non-bleeding lung; single-lumen + blocker is often more practical emergently than a DLT (Charya 2021 PMID 34527355)
massive_transfusion_protocol_pRBC_FFP_plateletsBalanced resuscitation per institutional MTP; correct fibrinogen with cryoprecipitateIVas neededSupport oxygen-carrying capacity + correct dilutional/consumptive coagulopathy; blood products have no single RxCUI → non_pharm (Charya 2021 PMID 34527355)

Plan: Massive hemoptysis — airway-first resuscitation → coagulopathy reversal + TXA → BAE → bronchoscopic tamponade → surgery (last resort)

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Hemoptysis with hypoxia / respiratory distress / inability to clear the airway / hemodynamic compromise — physiologic-massive (asphyxiation, the lethal mechanism; can occur at ≈150 mL)(life-threatening)
  • Volume surrogate (≥150 mL single expectoration / ≥100 mL/h / >100-600 mL/24h) OR any rate compromising gas-exchange/hemodynamics — the disposition gate (physiology > volume)
  • Hemoptysis on anticoagulant/antiplatelet OR with lab coagulopathy (INR↑, low platelets/fibrinogen, DIC/sepsis/liver)
  • CTA/angiography shows a localized bronchial-artery or nonbronchial-systemic culprit (~90% of cases)
  • Rasmussen aneurysm (TB cavity), AVM/HHT, or iatrogenic Swan-Ganz/PA rupture — pulmonary-artery source (~5%)(life-threatening)
  • Persistent/recurrent massive bleeding after BAE, or BAE failed/contraindicated/unavailable, or non-embolizable focal lesion(life-threatening)
  • Diffuse alveolar hemorrhage (ANCA vasculitis / anti-GBM / SLE) — diffuse bilateral, falling Hgb, often pulmonary-renal, may have minimal expectorated blood, with respiratory failure(life-threatening)

5. Follow-up

Route BACK to the underlying-disease engine for definitive management once airway secured — bronchiectasis airway clearance (pulm.bronchiectasis.core.v1), TB therapy (pulm.tuberculosis.v1), ABPA/aspergilloma steroids+antifungal (pulm.abpa.v1), vasculitis maintenance immunosuppression, malignancy oncology (onc.lung-cancer.core.v1); recurrence-prevention + repeat-BAE/surgery planning (Allwood Respiration 2021 PMID 33401266)

6. Sources

Guideline: No single society "massive hemoptysis" guideline exists — evidence floor: Charya life-threatening hemoptysis ICU review (J Thorac Dis 2021; PMID 34527355) + Earwood hemoptysis evaluation/management (AFP 2015; PMID 25955625) + CHEST nebulized-TXA RCT (Wand 2018; PMID 30321510) + Cochrane antifibrinolytics (2016; PMID 27806184) + BAE long-term series (Kim Respirology 2006 PMID 17052307; Lee Acta Radiol 2008 PMID 18210312) + PEXIVAS/RAVE for DAH (NEJM 2020 PMID 32053298; NEJM 2010 PMID 20647199); all confirmed current 2026-05-16

  1. pubmed.ncbi.nlm.nih.gov/34527355
  2. pubmed.ncbi.nlm.nih.gov/25955625
  3. pubmed.ncbi.nlm.nih.gov/12816036